Ikarian Capital’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

Ikarian Capital’s Portfolio ASLN Stock Details ASLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,428	Closed	-$6.27K	–	157
2024 Q1	$6.27K	Hold	4,428	–	–	﹤0.01%	136
2023 Q4	$6.53K	Hold	4,428	–	–	﹤0.01%	135
2023 Q3	$6.21K	Sell	4,428 -16,083	-78%	-$295K	﹤0.01%	137
2023 Q2	$29.8K	Hold	20,511	–	–	﹤0.01%	120
2023 Q1	$476K	Hold	20,511	–	–	0.11%	96
2022 Q4	$151K	Hold	20,511	–	–	0.04%	74
2022 Q3	$146K	Sell	20,511 -3,758	-15%	-$96.9K	0.03%	96
2022 Q2	$185K	Hold	24,269	–	–	0.03%	123
2022 Q1	$192K	Buy	24,269 +1,335	+6%	+$49.6K	0.03%	169
2021 Q4	$187K	Sell	22,934 -12,500	-35%	-$749K	0.03%	162
2021 Q3	$288K	Buy	35,434 +4,821	+16%	+$548K	0.02%	197
2021 Q2	$248K	Hold	30,613	–	–	0.02%	204
2021 Q1	$243K	Sell	30,613 -19,548	-39%	-$2.48M	0.01%	268
2020 Q4	$405K	Buy	+50,161	New	+$3.68M	0.02%	198

Other funds holding ASLN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Ikarian Capital's ASLN Position: Q2 2024 in Review

Ikarian Capital sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q2 2024, closing a stake of 4,428 shares — an estimated $6.27K sold.

Ikarian Capital first reported a position in ASLN in Q4 2020 and held it in 14 quarters. The position peaked at $476K in Q1 2023. 19 funds tracked by Wall St. Rank hold ASLN as of Q2 2024.

Ikarian Capital reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q2 2024 after selling out during the quarter.
Ikarian Capital sold 4,428 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q2 2024, an estimated $6.27K.
Ikarian Capital first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q4 2020 and held it in 14 quarters.
Ikarian Capital's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $476K in Q1 2023.
19 funds tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q2 2024.

Based on Ikarian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.